Healthcare professionals will soon be able to offer women the first vaginal estrogen product that treats both the vasomotor and vaginal symptoms of menopause. The FDA recently approved estradiol (Femring, Galen Holdings) vaginal ring for the treatment of moderate to severe vasomotor symptoms associated with menopause and treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with menopause. Femring will be available in pharmacies in June.
Targeted Drug Combination Reveals New Activity in Brain Tumors
December 28th 2021A combination of two targeted cancer drugs showed unprecedented, “clinically meaningful” activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by investigators from Dana-Farber Cancer Institute.